Cryptococcal fungemia in a neutropenic patient with AIDS while receiving caspofungin

Journal of Infection

Volumn 51, Issue 3, 2005, Pages

  Malhotra, Prashant ^a   Shah, Sanjiv S ^a   Kaplan, Mark ^a,b   McGowan, Joseph P ^a,c  

^a NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Caspofungin; Cryptococcus; HIV AIDS; Neutropenia

Indexed keywords

ATAZANAVIR; BLEOMYCIN; CASPOFUNGIN; CLINDAMYCIN; COTRIMOXAZOLE; DACARBAZINE; DOXORUBICIN; GENTAMICIN; LAMIVUDINE; PENTOXIFYLLINE; PIPERACILLIN PLUS TAZOBACTAM; PRIMAQUINE; RITONAVIR; STEROID; TENOFOVIR; VINBLASTINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; BRONCHOSCOPY; CANCER STAGING; CASE REPORT; CLINICAL FEATURE; CRYPTOCOCCOSIS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; FEBRILE NEUTROPENIA; HEPATITIS C; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; LUNG TOXICITY; MALE; PNEUMOCYSTIS PNEUMONIA; RISK FACTOR;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIFUNGAL AGENTS; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DRUG RESISTANCE, FUNGAL; FUNGEMIA; HIV INFECTIONS; HODGKIN DISEASE; HUMANS; MYCOSES; NEUTROPENIA; PEPTIDES, CYCLIC;

EID: 27644490269     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2005.01.002     Document Type: Article

References (15)

1. S.E. Vartivarian E.J. Anaissie G.P. Bodey Emerging fungal pathogens in immunocompromised patients: Classification, diagnosis, and management Clin Infect Dis Suppl 2 1993 S487-S491
2. W.T. Hughes D. Armstrong G.P. Bodey E.J. Bow A.E. Brown T. Calandra et al. Guidelines for the use of antimicrobial agents in neutropenic patients with cancer Clin Infect Dis 34 2002 730-751
3. T.J. Walsh H. Teppler G.R. Donowitz J.A. Maertens L.R. Baden A. Dmoszynska et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia N Engl J Med 351 2004 1391-1402
4. D.W. Denning Echinocandin antifungal drugs Lancet 362 2003 1142-1151
5. J.A. Sparano Human immunodeficiency virus associated lymphoma Curr Opin Oncol 15 2003 372-378
6. P. Hartmann U. Rehwald B. Salzberger C. Franzen V. Diehl Current treatment strategies for patients with Hodgkin's lymphoma and HIV Expert Rev Anticancer Ther 4 2004 401-410
7. T.G. Mitchell J.R. Perfect Cryptococcosis in the era of AIDS-100 years after the discovery of Cryptococcus neoformans Clin Microbiol Rev 8 1995 515-548
8. A.J. Mednick M. Feldmesser J. Rivers A. Casadevall Neutropenia alters lung cytokine production in mice and reduces their susceptibility to pulmonary cryptococcosis Eur J Immunol 33 2003 1744-1753
9. M.H. Kaplan P.P. Rosen D. Armstrong Cryptococcosis in a cancer hospital Cancer 39 1977 2265-2274
10. L. Ostrosky-Zeichner J.L. Soto-Hernandez V. Angeles-Morales et al. Effects of pentoxifylline or dexamethasone in combination with amphotericin B in experimental murine cerebral cryptococcosis: Evidence of neoroexcitatory pathogenic mechanisms Antimicrob Agents Chemother 40 1996 1194-1197
11. C.A. Hage K.L. Wood H.T. Winer-Muram S.J. Wilson G. Sarosi K.S. Knox et al. Pulmonary cryptococcosis after initiation of anti-tumor necrosis factor-α therapy Chest 124 2003 2395-2397
12. G. Samonis D.P. Kontoyiannis Infectious complications of purine analog therapy Curr Opin Infect Dis 14 2001 409-413
13. T.J. Walsh P. Pappas D.J. Winston et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever N Engl J Med 346 2002 225-234
14. M. Del Poeta M.C. Cruz M.E. Cardenas J.R. Perfect J. Heitman Synergistic antifungal activities of bafilomycin A1, fluconazole and the pneumocandin MK0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans Antimicrob Agents Chemother 44 2000 739-746
15. N. Singh Trends in the epidemiology of opportunistic fungal infections: predisposing factors and the impact of antimicrobial use practices Clin Infect Dis 33 2001 1692-1696